Unpredictable effects: Peptides can alter complex biological pathways, leading to unintended consequences
It also provides movement goals and a community of people on a similar journey for support and practical tips
Semaglutide in Type 2 Diabetic Adult Patients In a clinical trial, semaglutide showed superiority over dulaglutide to improve glucose control and weight loss greater than 5% in type 2 diabetic adult patients.[12] The study was randomized and open-label, meaning the participants knew what medication they received
Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies
The actor opened up about his body image struggles after being labeled gross and unattractive earlier in his career
See what else the data showed by downloading the full report: To view or add a comment, sign in The obesity drug market is worth $100B+
